LAROTRECTINIB

NCT02122913 📎

Regimen

Experimental
larotrectinib
Control
none

Population

NTRK fusion+ tumors across histologies incl. NSCLC

Key finding

ORR 75% (61-85); histology-agnostic TRK inhibitor activity

Source: PMID 29466156

Timeline

  • Enrollment start: 2014-05-04 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.59)
  • CSCO NSCLC 2025 ⚠️ OCR source